Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

nt with Janssen, total amounts in excess of the annual cap ("Excess Amounts") plus interest may not exceed $225 million.

The Company has recognized the Excess Amounts as a reduction to operating expenses in the current year as the Company's repayment of the Excess Amounts to Janssen is contingent and would become payable only after the third profitable calendar quarter for the product under the collaboration. Further, the Excess Amounts shall be reimbursable only from the Company's share of future full calendar quarter pre-tax profits (if any) after the third profitable calendar quarter for the product under the collaboration.

For the calendar year ended December 31, 2012, the Company's total share of collaboration expenses under the Agreement was $68.1 million. As of December 31, 2012, total Excess Amounts totaled $18.1 million, of which during the quarter ended December 31, 2012, $17.3 million was recorded as a reduction to research and development expense and $0.8 million was recorded as a reduction to general and administrative expense.

GAAP operating expenses were $40.6 million for the six months ended December 31, 2012, compared to $30.6 million for the six months ended December 31, 2011. Included in operating expenses for the six months ended December 31, 2012 is the $18.1 million reduction to operating expenses for Excess Amounts.

GAAP operating expenses were $16.7 million for the quarter ended December 31, 2012, compared to $16.0 million for the quarter ended December 31, 2011 and $23.9 million for the quarter ended September 30, 2012. Included in operating expenses for the quarter ended December 31, 2012 is the $18.1 million reduction to operating expenses for the Excess Amounts.

At December 31, 2012, the Company had cash, cash equivalents and marketable securities of $317.1 million, compared with $203.6 million at June 30, 2012. In addition, as of December 31, 2012, the Company had $26.6 million receivable from Jansse
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Boston, MA (PRWEB) July 31, 2014 ... ) finds itself flush with innovative adult stem cell ... patents and has three additional patent applications ... Office. , The patented inventions address two of the ... and regenerative medicine. Adult stem cells are difficult ...
(Date:7/30/2014)... , July 30, 2014  Decision Resources ... and medical directors in the United ... of biosimilar market penetration will be the level ... (MCOs) and the expected lower cost to patients. ... biosimilars that meet their pricing expectations in order ...
(Date:7/30/2014)... 2014 Selexis SA , a ... discovery and mammalian cell line development, announced today new ... will be presented at the 10th Annual Cell ... 8 – 10, 2014 at the Double Tree by ... following abstract will be presented during an oral presentation: ...
(Date:7/30/2014)... 30, 2014 BCC Research ( http://www.bccresearch.com ... for Enzymes in Industrial Applications , the global market ... $7.1 billion by 2018, registering a five-year compound annual ... to be recorded in the detergent enzyme segment with ... Enzyme technology has influenced almost every sector of industrial ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3
... N.J., Sept. 30 Informex ( http://www.informex.com ... of high-value chemistry for a broad range of applications, ... will occur on November 9, 2010 in Milwaukee, Wisconsin. ... Informex initiative to act as a knowledge conduit for ...
... Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in... -- COPENHAGEN, September 30, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... Offer for Movetis NV and Commencement of... -- DUBLIN, September 30, 2010 ... ... --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
Cached Biology Technology:Inaugural Pharma Exchange Conference Produced by Informex to Draw Together Milwaukee, Wisconsin Chemical Industry 2Inaugural Pharma Exchange Conference Produced by Informex to Draw Together Milwaukee, Wisconsin Chemical Industry 3Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 2Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 3Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 4Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 5Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 6Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 7Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 8Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 9Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 10Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 2Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 3Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 4Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 5Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 6Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 7Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 8
(Date:7/30/2014)... Scientists are searching through a massive collection of ... 50 years ago, and the effort is yielding fresh ... inhabited. , When the collection is fully curated, a ... the largest unbiased Dominican amber collection in the world, ... discovery thus far is that of a pygmy locust, ...
(Date:7/30/2014)... subject of major interest in neuroscience. A large ... distinct stages of Wallerian degeneration: transcription factor activation, ... gene expression responses in the distal segment of ... known, differences in gene expression between the proximal ... and co-workers from Nantong University, China used microarrays ...
(Date:7/30/2014)... analysis of the roughly 3,000 pieces is still in ... the results will be of major significance. "Amazingly often, ... species in Fushun amber that we found in Baltic ... , The Baltic amber comes from the Baltic Sea ... rich in finds are, e.g., the coastal regions of ...
Breaking Biology News(10 mins):Decades-old amber collection offers new views of a lost world 2Chinese mosquitos on the Baltic Sea 2
... invading virus hijacks a cell,s workings by imitating a ... cell signals, the virus destroys a defensive protein designed ... cell cultures, may represent a broader targeting strategy used ... for developing more effective treatments for infectious diseases. ...
... Escherichia coli a bacteria considered the ... is a friend. Cornell University biomolecular engineers have learned ... proteins for making pharmaceuticals cheaper and faster. ( Nature ... Cornell associate professor of chemical and biomolecular engineering, and ...
... (a treatment that involves temporarily inserting and blowing up ... widen it) on veins in the neck and chest ... the venous abnormalities found in those with multiple sclerosis ... the Society of Interventional Radiology,s 37th Annual Scientific Meeting ...
Cached Biology News:To drive infections, a hijacking virus mimics a cell's signaling system 2From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals 2Interventional radiology: Mitigating symptoms, improving quality of life of MS patients 2Interventional radiology: Mitigating symptoms, improving quality of life of MS patients 3
MOUSE ANTI RAT KAPPA/LAMBDA:HRP Immunogen: MARK-1: Rat kappa light chains (IR202 and IR968)MARL-15: Rat lambda light chains (RH58, IR31)...
Request Info...
SAIVI Alexa Fluor 680 injectable contrast agent *bovine serum albumin*...
RABBIT ANTI QUINOLINIC ACID...
Biology Products: